Key facts
- This page summarizes Abpro Bio International, Inc.'s Form 3 filing for Abpro Holdings, Inc. (ABP).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Nov 2024, 21:00.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") on November 13, 2024, of an aggregate of 16,507,334 shares of Common Stock (the "Shares") pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro Corporation, a Delaware corporation ("Abpro"), relating to the business combination between the Issuer and Abpro (the "Business Combination").
Footnote F2
The Shares are comprised of (i) 13,656,600 shares issued as merger consideration, (ii) 983,333 shares transferred from Atlantic Coastal Acquisition Management II LLC to the reporting person, in connection with the closing of the Business Combination, (iii) 622,467 shares issued in a private placement (the "PIPE Offering") concurrent with the closing of the Business Combination, and (iv) 1,244,934 shares issued as incentive shares in connection with the PIPE Offering.